Filed in archive
Drugs, Vaccines and Therapeutics
by ruth on September 28, 2007
According to Phase II clinical trial data with 130 patients, an experimental drug called pertuzumab prolonged the survival time for women with stage 3 recurrent ovarian cancer. 
Pertuzumab is a monoclonal antibody being developed by Genentech as a chemotherapeutic drug against prostate, breast, and ovarian cancers.
The results were presented in the recently concluded European Cancer Conference held in Barcelona, Spain. The Phase II study is now closed, and a larger Phase 3 study of pertuzumab set to include hundreds of U.S. women is being planned.
Pertuzumab is a monoclonal antibody being developed by Genentech as a chemotherapeutic drug against prostate, breast, and ovarian cancers.
In the study, pertuzumab was administered in combination with a standard chemotherapy agent sometime after the initial treatments had been given, and after the re-emergence of cancer. Makhija said the new combination added weeks to the standard survival period for recurrent patients, and the drug combo was well-tolerated by the body and caused minimal side effects.
The results were presented in the recently concluded European Cancer Conference held in Barcelona, Spain. The Phase II study is now closed, and a larger Phase 3 study of pertuzumab set to include hundreds of U.S. women is being planned.
Tags:
pertuzumab
cancer
genentech
ovarian+cancer
monoclonal+antibody
biotech
recurrent+ovarian
pertuzumab+
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/94096
Addthis
Ask
Blinklist
del.icio.us
Digg
Fark
Facebook
Google
Lycos
Ma.gnolia
Mr Wong
Netscape
Netvousz
Newsvine
Reddit
StumbleUpon
Slashdot
Tailrank
Technorati
Wink
Yahoo
Vote for Pertuzumab Boosts Survival in Recurrent Ovarian Cancer Patients:
|
Rating: 5.00 out of 3 vote(s) cast.
|
Subscribe
Use the search to look for other interesting posts
| RSS |  See all blog subscribe options |
 What is RSS? | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Newsletter | |
| Follow us on Twitter! |
